Regeneron's (REGN) Acquisition of Checkmate (CMPI) Supports Thesis of "Uptick in M&A" in SMID-cap Biotechs - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $728.00 price target on Regeneron Pharma (NASDAQ: REGN) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
